|
Family Blood Pressure Program - SAPPHIRe Network Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about Family Blood Pressure Program - SAPPHIRe Network conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Family Blood Pressure Program - SAPPHIRe Network Clinical research trials and Family Blood Pressure Program - SAPPHIRe Network health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like Family Blood Pressure Program - SAPPHIRe Network. Family Blood Pressure Program - SAPPHIRe Network Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a Family Blood Pressure Program - SAPPHIRe Network clinical trial. Subjects frequently get the best healthcare possible for their Family Blood Pressure Program - SAPPHIRe Network condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "F" Clinical Trials Conditions > Family Blood Pressure Program - SAPPHIRe Network  Family Blood Pressure Program - SAPPHIRe Network
Family Blood Pressure Program - SAPPHIRe Network
For Condition: Hypertension,Heart Diseases,Cardiovascular Diseases
Status: No longer recruiting
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To map the major genetic loci underlying hypertension in approximately 1700 sibling pairs of Asian-Pacific Chinese and Japanese origin. The study consists of a two grant network, which in turn is part of an NHLBI initiative, the Family Blood Pressure Program consisting of four networks.
Details: BACKGROUND: Hypertension, a complex disease involving the interplay of genetic and environmental factors, affects an estimated 50 million Americans and is a major predisposing factor for myocardial infarction, vascular disease, stroke, and renal failure. It has been estimated from segregation analysis and twin studies that approximately 45 percent of the interindividual differences in blood pressure are accounted for by genetic differences. The identification of the genes whose variants contribute to high blood pressure will have far-reaching effects on our understanding of the pathophysiology of the circulation and may suggest new preventive measures and rational therapeutic approaches. One of the principal advantages of the genetic approach is that it identifies primary molecular defects. As a result, it will be possible to stratify the general hypertensive population into subgroups based on genotype and intermediate phenotype and thereby evaluate preventive strategies and therapeutic approaches in more homogeneous groups. In addition, the identification of hypertensive genes also provides the basis for an understanding of the interactions between genes and environmental factors. It is very likely that particular environmental variables exert their effects only in the presence of certain genotypes. Until recently, the techniques for dissecting the genetic determinants of high blood pressure were not available or were not developed to an extent that would make the Family Blood Pressure Program initiative feasible. However, several recent advances in technology and analytical methods, together with the rapid construction of genetic maps, have substantially improved the chances of detecting these genetic factors. The concept for the Family Blood Pressure Program was conceived in the Report of the Expert Panel on Genetic Strategies for Heart, Lung, and Blood Diseases. The initiative was approved by the Arteriosclerosis, Hypertension, and Lipid Metabolism Advisory Committee (AHLMAC) in March, 1993. The genetic-epidemiological aspects were approved by the Clinical Applications and Prevention Advisory Committee (CAPAC) in February, 1993. The Request for Applications was released in March, 1994. Awards were made in September, 1995. DESIGN NARRATIVE: The study focuses attention on an Asian population in order to reduce heterogeneity of the genetic background. In 1995, a genetic network was established in the San Francisco Bay Area, Hawaii, and Taiwan, recruiting an estimated 1,700 affected hypertensive sibpairs plus several multigenerational hypertensive pedigrees of Asian Pacific Chinese and Japanese. Linkage analysis is used to map and identify the genes for hypertension in this ethnic group. A new genetic map of the human genome with 2041 ordered polymorphic markers with an average interval of less than 3 cM has been reported. Such a dense map of polymorphic markers makes it plausible to propose linkage analysis of complex traits. A total genomic search is performed on 1700 affected sibpairs and family members. In addition, the candidate gene approach is also used. To address the possibility of heterogeneity of the hypertensive trait, a number of intermediate phenotypes is studied that may help identify more homogeneous subgroups of hypertension. For example, Asians and Pacific Islanders have an increased risk for hypertension, dyslipidemia, and glucose intolerance (Syndrome X) that are associated with hyperinsulinemia. Therefore, hypertension is investigated according to insulin sensitivity vs. resistance as well as other intermediate phenotypes related to hypertension pathophysiology such as renin, Ang II, and endothelin. The hypothesis is that by focusing on possible hypertensive subsets with well defined phenotypes, the possibility is enhanced of gene identification for hypertension in these patients. The third approach examines the hypothesis that there exists a dominant locus determining hypertension in a subset of affected individuals using the analysis of multigenerational pedigrees with 10-13 meiosis separating affected members. If such a subset exists, this approach would reduce the likelihood of heterogeneity and increase the probability of revealing genetic linkage. Once major gene loci are identified, it will be important to determine the prevalence of these loci in the overall population and the risk associated with their loci for the development of hypertension. Therefore, the genetic epidemiology of the loci are studied using epidemiological methodologies such as association studies and case control analysis on well characterized populations in Hawaii and Taiwan that have been studied prospectively for many years. The Family Blood Pressure Program, including the SAPPHIRe Network, was renewed in FY 2000. The Family Blood Pressure Program as a whole will carry out five specific aims in the renewal period. These aims can be grouped according to two complementary themes: First, the investigators will create and analyze a database of blood pressure-related phenotype and genotype data from all FBPP participants (Aim 1). Within linked regions, they will identify allelic variation within positional candidate genes and evaluate the relationship of these polymorphisms with blood pressure levels and hypertension status (Aims 2 and 3). Second, they will use quantitative measures of target organ damage to identify genes that influence susceptibility to develop hypertensive heart and kidney diseases (Aims 4 and 5). In addition to the Program specific aims, each network, including SAPPHIRe, will carry out its own specific aims alone, based on unique aspects of their population and interests and expertise of the investigators. SAPPHIRe investigators plan to refine the hypertensive phenotype in the study population by assessing the intermediate phenotype of insulin resistance using the oral glucose tolerance test and steady state plasma glucose assay. They will also use novel molecular genetic approaches to enrich genomic DNA for common genetic variations and develop proteomic approaches to identify proteins that are differentially expressed in plasma and urine of the SAPPHIRe participants.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: No eligibility criteria
Total Enrollment:
Location and Contact Information:
Overall Study Official:
JessCurb, , University of Hawaii
Additional Information:
Study ID Numbers: 1154;
Study Start Date: September 1995
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00005270
Other Cardiovascular Diseases Studies:
1. Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study)
2. Genetic Epidemiology of Blood Pressure Intervention
3. Family Blood Pressure Program - GenNet Network
4. The Role of Angiotensin Type I Receptor in the Regulation of Human Coronary Vascular Function
5. Improving Service Delivery through Access Points
Related Studies:
Other Cardiovascular Diseases Clinical Trials
Other Clinical Trials
Other Clinical Trials
Family Blood Pressure Program - SAPPHIRe Network
|
|
|
|
|
|
|
|
